Abstracts Archive - Page 2237 of 2425 - ACR Meeting Abstracts

Abstract Number: 194 • 2013 ACR/ARHP Annual Meeting
Team Managed Care From a Patient’s Perspective: A Study Of Biological Patients At a Canadian Centre
Dawn Heap¹, Margaret Saldanha¹, Melissa Deamude¹, Cynthia Mech², Helena Ross¹, Kathy Kislinsky¹, Lauri Vanstone³, Arthur N. Lau⁴ and William G. Bensen⁵, ¹Dr. William G. Bensen, Rheumatology Health Team, St. Joseph's Hospital Hamilton, Hamilton, ON, Canada, ²Dr. William G. Bensen, Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, ³Dr. William Bensen Rheumatology Biologic Clinic, Rheumatology Health Team, Hamilton, ON, Canada, ⁴Rheumatology and Clinical Epidemiology, Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ⁵Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada
Background/Purpose: In Canada, there is a widening care gap in Inflammatory Arthritis due to the increased aging population, higher disease prevalence, dwindling numbers of practicing…
Abstract Number: 195 • 2013 ACR/ARHP Annual Meeting
Major Cost Savings Associated With Reduced Biologic Dosing Frequency In Inflammatory Arthritis
Claire-Louise Murphy¹, Miriam O'Sullivan², Sohail Awan³, Shawn Chavrimootoo⁴, Clara Bannon³, Linzi Martin², Trevor Duffy², Eithne Murphy² and Maurice Barry², ¹Rheumatology, Connolly hospital, Dublin 15, Dublin, Ireland, ²Rheumatology, Connolly hospital, Dublin, Ireland, ³Blanchardstown, Connolly hospital, Dublin, Ireland, ⁴rheumatology, Connolly hospital, Dublin, Ireland
Background/Purpose: Biologic agents are highly effective in Inflammatory Arthritis (IA) but are extremely expensive. A sustained reduction in biologic dosing frequency would lead to major…
Abstract Number: 196 • 2013 ACR/ARHP Annual Meeting
Uptake Of The American College Of Rheumatology’s Rheumatology Clinical Registry: Quality Measure Summary Data
Jinoos Yazdany¹, Salahuddin Kazi², Rachel Myslinski³ and Melissa Francisco⁴, ¹Medicine, University of California, San Francisco, San Francisco, CA, ²Internal Medicine/Rheumatology, UT Southwestern Medical Center, Dallas, TX, ³Practice, Advocacy, & Quality, American College of Rheumatology, Atlanta, GA, ⁴Registries & Health Informatics, American College of Rheumatology, Atlanta, GA
Background/Purpose: The RCR provides ACR members with an infrastructure for quality reporting related to rheumatoid arthritis, gout, osteoarthritis, osteoporosis, and drug safety. Currently in its…
Abstract Number: 139 • 2013 ACR/ARHP Annual Meeting
Pain and Other Symptoms During The Childhood Of Fibromyalgia Patients
Robert S. Katz¹, Alexandra Small², Ben J. Small³ and Susan Shott⁴, ¹Rush Medical College, Chicago, IL, ²University of Illinois Medical School, Chicago, IL, ³Rush University Medical School, Chicago, IL, ⁴Rush University Medical Center, Chicago, IL
Background/Purpose: We investigated the severity of pain and other symptoms during childhood, before age 12 and before age 18, that might be related to fibromyalgia…
Abstract Number: 119 • 2013 ACR/ARHP Annual Meeting
Routine Assessment Of Patient Index Data 3 In Fibromyalgia: A Rapid and Reliable Instrument For Evaluating Disease Severity?
Ece Kaptanoglu, Ozlem Sahin, Yunus Durmaz, Ahmet Kivanc Cengiz and Sami Hizmetli, Rheumatology, Cumhuriyet University, Sivas, Turkey
Background/Purpose: Routine Assessment of Patient Index Data 3 (RAPID 3) is a patient based questionnaire which was designed for evaluation of disease activity without formal…
Abstract Number: 100 • 2013 ACR/ARHP Annual Meeting
Myocardial Infarction and Mortality after Joint Surgery in Patients with Rheumatoid Arthritis Compared with the General Population
Joanne Tropea¹, Mark Tacey², Megan Bohensky², Caroline Brand², Ian Wicks³ and Sharon Van Doornum², ¹Melbourne EpiCentre, Royal Melbourne Hospital, Melbourne, Australia, ²Melbourne EpiCentre, The University of Melbourne, Melbourne, Australia, ³Rheumatology Unit, Royal Melbourne Hospital, Melbourne, Australia
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of myocardial infarction (MI) and post-MI fatality compared with the general population. In a previous…
Abstract Number: 101 • 2013 ACR/ARHP Annual Meeting
Trends In Prescription Of Opioids From 2003-2009 In Persons With Knee Osteoarthritis
Elizabeth Wright¹, Jeffrey N. Katz², Stanley Abrams³, Daniel H. Solomon⁴ and Elena Losina⁵, ¹Orthopedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, ²Rheumatology and Orthopedics, Brigham and Women's Hospital, Boston, MA, ³Orthopedics and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, ⁴Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ⁵Orthopaedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Osteoarthritis (OA) of the knee is a painful condition affecting ~13% of persons >65 years of age. OA is often accompanied by comorbidities. Effective…
Abstract Number: 102 • 2013 ACR/ARHP Annual Meeting
Association Of Area-Level Socioeconomic Status With Pain and Function At Presentation For Total Knee Arthroplasty
Candace H. Feldman¹, Yan Dong², Jeffrey N. Katz³, Laurel Donnell-Fink⁴ and Elena Losina², ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Orthopaedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, ³Rheumatology and Orthopedics, Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: Prior studies suggest that individuals with lower socioeconomic status (SES) both under-utilize joint replacement procedures and present with increased pain and poorer function. Area-level…
Abstract Number: 103 • 2013 ACR/ARHP Annual Meeting
Proportion Of U.S. Older Adults Meeting Inclusion Criteria For 2010 ACR Recommendations On Glucocorticoid-Induced Osteoporosis
Robert A. Overman^1,2, Joshua C. Toliver³, Jun-Yen Yeh⁴, Margaret L. Gourlay⁵ and Chad L. Deal⁶, ¹Eshelman School of Pharmacy - Division of Pharmaceutical Policy and Outcomes, University of North Carolina, Chapel Hill, NC, ²Rheumatology, Cleveland Clinic, Cleveland, OH, ³Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, ⁴Arnold & Marie Schwartz College of Pharmacy and Health Sciences - Divison of Pharmaceutical Sciences, Long Island University, Brooklyn, NY, ⁵Family Medicine, University of North Carolina, Chapel Hill, NC, ⁶Dept of Rheum & Imm Dis /A 50, Cleveland Clinic, Cleveland, OH
Background/Purpose: Glucocorticoid-induced osteoporosis (GIO) is the most common cause of secondary osteoporosis. Fracture related to GIO increases a patient’s mortality risk and reduces quality of…
Abstract Number: 104 • 2013 ACR/ARHP Annual Meeting
Incidence Of Osteoporotic Hip Fractures In Estonia Between 2005 and 2012
Mikk Jürisson^1,2, Anneli Uusküla¹, Riina Kallikorm³, Sigrid Vorobjov^2,4 and Margus Lember³, ¹Department of Public Health, Faculty of Medicine, Tartu University, Tartu, Estonia, ²East Tallinn Central Hospital, Tallinn, Estonia, ³Department of Internal Medicine, Faculty of Medicine, Tartu University, Tartu, Estonia, ⁴National Institute for Health Development, Tallinn, Estonia
Background/Purpose: Monitoring the incidence of hip fractures is essential to measuring population health and the value of improvements in health care. Data on recent trends…
Abstract Number: 105 • 2013 ACR/ARHP Annual Meeting
Medication Use With Denosumab (Prolia^®) In a Large Claims Database In The United States
Emily Durden¹, Lung-I Cheng², Elnara Eynullayeva³, Christopher Gregory³ and Bradley Stolshek², ¹Truven Health Analytics, Bethesda, MD, ²Amgen, Inc., Thousand Oaks, CA, ³Truven Health Analytics, Washington, DC
Background/Purpose: Persistence and compliance with osteoporosis therapies is associated with significantly fewer vertebral, nonvertebral and hip fractures. A number of studies have examined medication-taking behavior…
Abstract Number: 106 • 2013 ACR/ARHP Annual Meeting
Antinuclear Antibodies Positive But No Autoimmune Disease
M Herold¹ and Werner Klotz², ¹Internal Medicine VI, Medical University of Innsbruck, Innsbruck, Austria, ²Internal Medicine VI, Innsbruck Medical University, Innsbruck, Austria
Background/Purpose: Antinuclear antibodies (ANAs) are tested in sera of patients suspicious of an autoimmune disorder. ANAs are part in many classification criteria of autoimmune (AI)…
Abstract Number: 107 • 2013 ACR/ARHP Annual Meeting
Duration Of Symptoms Before Diagnosis In Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Merete Lund Hetland^1,2 and Jan Sørensen³, ¹The Danish Rheumatologic Database (DANBIO), Glostrup Hospital, Glostrup, Denmark, ²Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark, ³Center for Applied Health Services Research, University of South Denmark, Odensen, Denmark
Background/Purpose: Early diagnosis is important for the treatment of many rheumatic diseases. Little is known about the duration of symptoms before establishment of diagnosis, and if the…
Abstract Number: 108 • 2013 ACR/ARHP Annual Meeting
Cost-Effectiveness Analysis Of Diagnostic Tests In The Work-Up Of Patients With Intermediate Risk Of Developing Rheumatoid Arthritis
Jolanda J. Luime¹, Maureen Rutten², Leander Buisman², Mark Oppe² and Johanna M.W. Hazes³, ¹Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands, ²Institute for Medical Technology Assessment, Erasmus University, Rotterdam, Netherlands, ³Rheumatology, Erasmus MC, Rotterdam, Netherlands
Background/Purpose: With technological improvements in genomics, cytomics and metabolomics many promising biomarkers for stratifying individuals at risk of developing Rheumatoid Arthritis will enter the market. …
Abstract Number: 109 • 2013 ACR/ARHP Annual Meeting
Comparison Of Characteristics In Rheumatoid Arthritis Between International and National Databases In Europe: A Systematic Literature Review
E. Gvozdenovic¹, R. Koevoets¹, J. Langenhoff², C.F. Allaart¹ and R. Landewe³, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: RA (Rheumatoid Arthritis) cohorts and registers are established for daily practice in clinical care. There are still differences between registries in disease activity and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].